Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HY 0007

Next Previous
Drug Profile

HY 0007

Alternative Names: HY-0007; HY-07121

Latest Information Update: 29 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Huiyu Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD8 positive T lymphocyte stimulants; Interleukin 15 receptor agonists; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 29 Jan 2026 Early research in Solid tumours in Europe (IV) prior to January 2026 (Sichuan Huiyu Pharmaceuticals pipeline, January 2026)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 24 Oct 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT06639256)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top